Events & presentations
Corporate presentations, conference posters and scientific talks, together with the webcasts of quarterly results and corporate update calls. Every document is available to download.
80 events from 2017 to 2025. 39 carry a downloadable presentation or poster: 40 files in total.
Webcast recordings are hosted by the conference or webcast provider and open in a new tab. Older recordings may have expired at source; the presentation files below do not expire, because they are served from this site.
19 May 2025
Brainstorm Cell Therapeutics - Corporate Update
8 May 2025
Presentation at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, May 6 - 10, 2025
30 December 2024
Brainstorm Cell Therapeutics - Corporate Update
11 December 2024
BrainStorm Cell Therapeutics KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS)
27 October 2024
Poster Presentations at the 2024 Annual NEALS Meeting October 21- 24, 2024
1 October 2024
Investor Presentation - October 2024
14 August 2024
Brainstorm Cell Therapeutics Second Quarter 2024 Earnings Call
8 July 2024
Corporate Mid-Year Update on NurOwn Program
9 April 2024
NurOwn Program Update Call Regarding Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
4 March 2024
Poster Presentation at the 2024 MDA Clinical and Scientific Conference
17 November 2023
6th Annual ALS Research Symposium
14 November 2023
Third Quarter 2023 Financial Results and Corporate Update Call
18 October 2023
Brainstorm Cell Therapeutics Investor Call
14 August 2023
Second Quarter 2023 Financial Results and Corporate Update Call
5 July 2023
New biomarker data from the Phase 3 trial, presented at the Gordon Research Conference
15 May 2023
First Quarter 2023 Financial Results and Corporate Update Call
30 March 2023
Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Update Call
27 March 2023
Brainstorm Investor Call
20 March 2023
Poster Presentation at the 2023 MDA Clinical and Scientific Conference
20 January 2023
13th Annual California ALS Research Summit
9 January 2023
Biotech Showcase 2023
14 November 2022
Third Quarter 2022 Financial Results and Corporate Update Call
6 November 2022
BrainStorm's Poster Presentation at the 21st Annual NEALS Meeting
26 October 2022
Poster Presentation at ECTRIMS 2022
7 October 2022
ALS One Research Symposium
15 August 2022
Second Quarter 2022 Financial Results and Corporate Update Call
2 June 2022
CMSC 2022 Meeting
1 June 2022
Poster Presentation at the ENCALS Meeting 2022, Edinburgh
26 May 2022
ISEV 2022 Annual Meeting, Lyon France
25 May 2022
ALS Drug Development Summit, Boston MA
16 May 2022
First Quarter 2022 Financial Results and Corporate Update Call
4 May 2022
ISCT 2022 Annual Meeting
28 March 2022
BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update
16 March 2022
Presentation at the MDA Clinical and Scientific Conference
27 January 2022
BrainStorm to Present at 12th Annual California ALS Research Summit
7 December 2021
BrainStorm to Present New Biomarker Data on NurOwn at the 32nd International Symposium on ALS/MND
30 November 2021
BrainStorm to Present at the 4th Annual ALS ONE Research Symposium
15 November 2021
Brainstorm Cell Therapeutics Third Quarter 2021 Earnings Call
14 October 2021
BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS
6 October 2021
BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting
26 April 2021
BrainStorm First Quarter 2021 Financial Results and Corporate Update
26 February 2021
10th Annual SVB Leerink Global Healthcare Conference
4 February 2021
BrainStorm-Cell Therapeutics Fourth Quarter and Fiscal Year 2020 Financial Results and Corporate Update
30 September 2020
Annual Northeast ALS (NEALS) Meeting
24 September 2020
WuXi Apptec- Collaborations That Transform Meeting (Multiple Sclerosis)
14 September 2020
2020 CIRM Grantee Meeting
9 September 2020
Advanced Therapies & Expo 2020
13 August 2020
Canaccord Genuity 40th Annual Growth Conference
5 August 2020
Financial Results for the Second Quarter of 2020 and Corporate Update
4 August 2020
Company non-confidential Presentation August 2020
8 July 2020
Key Opinion Leader (KOL) Webinar on the Company's Alzheimer's Disease (AD) Clinical Program
18 June 2020
Raymond James Human Health Innovations Conference
8 June 2020
Dr. Ralph Kern, MD, President and Chief Medical Officer, presents at Bio Digital 2020
7 May 2020
Brainstorm Cell Therapeutics First Quarter 2020 Investor Earnings Call
18 March 2020
BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19
18 February 2020
BrainStorm Cell Therapeutics - Fourth Quarter 2019 Investor Earnings Call
11 February 2020
BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference
24 January 2020
Dr. Ralph Kern at the ALS Research Forum, January 2020
13 January 2020
Brainstorm Cell Therapeutics Presentation at the 2020 Biotech Showcase
12 January 2020
Brainstorm Cell Therapeutics Presentation at the 3rd Annual Neuroscience Innovation Forum
6 January 2020
BrainStorm Cell Therapeutics at the 2nd Annual Sachs Associates Neuroscience Innovation Forum
4 December 2019
Brainstorm Cell Therapeutics Inc. 30th International Symposium on ALS/MND
14 November 2019
Brainstorm Cell Therapeutics Inc. Third Quarter 2019 Business Update Conference Call
29 October 2019
CEO Presentation at the Cell Series UK 2019 Conference
28 October 2019
CFO Presentation at the Dawson James Conference 2019
13 August 2019
Brainstorm Cell Therapeutics Inc. Second Quarter 2019 Business Update Conference Call
4 June 2019
Brainstorm Cell Therapeutics presentation at the Bio International Convention
30 May 2019
Brainstorm Cell Therapeutics Inc. at the 2019 CMSC Annual Meeting, Seattle WA
25 February 2019
Brainstorm Cell Therapeutics presentation at the 12th Annual European Life Sciences CEO Forum
7 January 2019
BrainStorm Cell Therapeutics presentations at the 37th Annual JP Morgan Healthcare Conference - 2019 Biotech Showcase
13 November 2018
Presentation at the Biotech and Money Investival Showcase 2018
5 September 2018
Brainstorm Presentation at the H.C. Wainwright & Co 20th Annual Investor Conference
23 July 2018
BrainStorm Cell Therapeutics - Second Quarter 2018 Earnings Call
14 May 2018
BrainStorm Cell Therapeutics - First Quarter 2018 Earnings Call
18 April 2018
CEO's Presentation at the 2018 ARM Cell & Gene Investor Conference
8 March 2018
Annual Financials Investor Call
13 February 2018
CEO's Presentation at the 2018 Bio CEO & Investor Conference
10 January 2018
CEO's Presentation at the 2018 Biotech Showcase Conference
18 September 2017
Investor Presentation - September 2017
1 October 2024
Investor Presentation October 2024 (alternate file)
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.